Transforming dysfunctional CD8+ T cells into natural controller-like CD8+ T cells: can TCF-1 be the magic wand?
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
3
6
2022
Statut:
ppublish
Résumé
HIV infection results in defective CD8+ T cell functions that are incompletely resolved by antiretroviral therapy (ART) except in natural controllers, who have functional CD8+ T cells associated with viral control. In this issue of the JCI, Perdomo-Celis et al. demonstrated that targeting the Wnt/transcription factor T cell factor 1 (Wnt/TCF-1) pathway in dysfunctional CD8+ T cells led to gains in stemness phenotype, metabolic quiescence, survival potential, response to homeostatic γ-chain cytokines, and antiviral capacities, similar to profiles of functional CD8+ T cells in natural controllers. Although reprogramming might not sufficiently reverse the imprinted dysfunction of CD8+ T cells in HIV infection, these findings outline the Wnt/TCF-1 pathway as a potential target to reprogram dysfunctional CD8+ T cells in efforts to achieve HIV remission.
Identifiants
pubmed: 35642630
pii: 160474
doi: 10.1172/JCI160474
pmc: PMC9151690
doi:
pii:
Substances chimiques
T Cell Transcription Factor 1
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Comment
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIMH NIH HHS
ID : R01 MH106466
Pays : United States
Organisme : NIH HHS
ID : P51 OD011092
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI147749
Pays : United States
Commentaires et corrections
Type : CommentOn
Références
Nat Commun. 2017 May 03;8:15050
pubmed: 28466857
Nat Immunol. 2021 Aug;22(8):1020-1029
pubmed: 34312547
Nat Rev Immunol. 2012 Nov;12(11):749-61
pubmed: 23080391
JCI Insight. 2021 Feb 8;6(3):
pubmed: 33351785
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
EBioMedicine. 2019 Apr;42:86-96
pubmed: 30879922
Biochem J. 2015 Sep 1;470(2):207-21
pubmed: 26348909
Cell. 2019 Jan 10;176(1-2):404
pubmed: 30633907
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
J Exp Med. 2000 Jul 3;192(1):63-75
pubmed: 10880527
Nature. 2017 Dec 21;552(7685):404-409
pubmed: 29236683
Emerg Microbes Infect. 2022 Dec;11(1):391-405
pubmed: 34985411
J Virol. 2021 Feb 3;:
pubmed: 33536176
Nat Immunol. 2021 Feb;22(2):229-239
pubmed: 33398179
Blood Adv. 2018 Jul 24;2(14):1685-1690
pubmed: 30021780
Immunity. 2010 Aug 27;33(2):229-40
pubmed: 20727791
Immunity. 2019 Nov 19;51(5):840-855.e5
pubmed: 31606264
Immunity. 2019 Dec 17;51(6):1043-1058.e4
pubmed: 31810882
Cell Mol Immunol. 2021 May;18(5):1262-1277
pubmed: 32341523
Nat Med. 2009 Jul;15(7):808-13
pubmed: 19525962
Nat Rev Immunol. 2021 Jan;21(1):5-19
pubmed: 32764670
J Exp Med. 2006 Oct 2;203(10):2281-92
pubmed: 16954372
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202771
J Clin Invest. 2022 Jun 1;132(11):
pubmed: 35380989
Nat Immunol. 2002 Nov;3(11):1061-8
pubmed: 12368910
Nature. 1995 Mar 2;374(6517):70-4
pubmed: 7870176
Immunity. 2015 Sep 15;43(3):591-604
pubmed: 26362266
Blood. 2012 Oct 25;120(17):3466-77
pubmed: 22955926
Nat Med. 2020 Apr;26(4):498-501
pubmed: 32235883
Sci Immunol. 2020 Jul 3;5(49):
pubmed: 32620560